For generations, millions of people believed in a statement that seemed indisputable: “People who can’t lose weight lack discipline and willpower.” The answer to virtually every case of obesity was to eat less, resist temptation and exercise more. The arrival of GLP-1–based medications, popularly known as “weight-loss injections” (GLP-1 drugs), however, has been prompting a profound shift in this way of thinking. For the first time, patients are describing an experience that challenges old certainties: food stops taking up permanent space in the mind, as if the brain had finally silenced a dialogue that once seemed inevitable.
Beyond being a new weight-loss strategy, GLP-1 agonists are helping physicians and researchers better understand how hunger, satiety, reward and eating behavior are biologically regulated. The focus of the discussion moves away from the idea of "willpower" toward recognizing that obesity is a complex disease, the result of interactions among genetics, hormones, metabolism, the brain, the environment and psychological factors.
When hunger is no longer just a choice
"GLP-1–based medications have helped demonstrate, in a very concrete way, that hunger is not simply a choice, a moral weakness or a lack of discipline. It is regulated by a complex biological network involving the gut, the brain, adipose tissue, the pancreas and a range of hormones," says endocrinologist Alexandre Hohl, a professor of endocrinology and metabolism at the Universidade Federal de Santa Catarina (UFSC).
This understanding is supported by a growing body of scientific research on so-called "food noise." In 2025, an international panel of experts from the American Society for Nutrition proposed a formal definition of the term: persistent, unwanted thoughts about food that can cause emotional distress and affect quality of life. The researchers note that many patients only realized how intense this phenomenon was after it subsided with the use of GLP-1 agonists, revealing that what was previously interpreted as a lack of self-control may reflect neurobiological mechanisms related to hunger and reward.
The meaning of "food silence"
This is where so-called “food silence” comes from. Hohl explains that this is an expression patients use to describe the reduction in persistent, intrusive thoughts about food. “Neuroimaging studies show changes in brain regions involved in appetite, emotion and reward. In practice, food may still be pleasurable, but it no longer occupies such a dominant place in one’s thoughts," the endocrinologist explains.
These accounts have sparked interest within the psychology of eating behavior. Recent reviews suggest that the partial disappearance of "food noise" may represent much more than reduced appetite. For some people, it means experiencing a less conflicted relationship with food for the first time.
At the same time, researchers warn that this new scenario also requires emotional adjustment. When eating stops working as the main strategy for coping with anxiety, stress or frustration, other psychological needs may emerge and should be addressed through specialized care. The very group that proposed the CIRO (Cue-Influencer-Reactivity-Outcome) conceptual model emphasizes that "food noise" is still being scientifically defined and should not be confused with eating disorders or reduced to a single biological explanation.
The medication doesn’t treat everything
Reduced hunger, however, does not mean that every dimension of obesity is automatically resolved. Self-esteem, body image, emotional distress, patterns learned over a lifetime and social factors continue to influence eating behavior. That is why international guidelines continue to recommend that treatment be delivered by multidisciplinary teams, integrating medical care, nutritional guidance, physical activity and, when needed, psychological support.
"GLP-1 can reduce food impulsivity, but we shouldn’t confuse a reduction in appetite with the automatic resolution of all the emotional, social and psychological factors involved in eating behavior. In people with a suspected eating disorder, psychological, psychiatric and nutritional care remains essential," Hohl emphasizes.
This concern also appears in the scientific literature. Clinical studies show that the medications reduce hunger, cravings for highly palatable foods and energy intake, but they do not replace the building of new habits, nor do they, on their own, eliminate emotional issues associated with eating. A study published in 2025 involving people using semaglutide to treat obesity observed a marked reduction in "food noise" and improvements in perceived mental health and quality of life. But the authors themselves stress that these results need to be confirmed by prospective studies and accompanied by individualized clinical assessment.
A new perspective on obesity
For Alexandre Hohl, GLP-1–based medications are paving the way for two inseparable legacies. On one side, there is a new generation of treatments, with more effective drugs, combinations of different hormones and more individualized strategies; on the other, a cultural and scientific shift that is transforming the way obesity is understood. "The new treatments show that it is possible to pharmacologically modify hunger, satiety, food reward and metabolic response. This confirms that these phenomena have measurable biological bases. Perhaps the greatest legacy is that we finally understand, once and for all, that body weight is not merely the result of individual choices," he reflects.
This paradigm shift may also help reduce one of the biggest obstacles faced by people with obesity: stigma. Recognizing that hunger, cravings and reward are regulated by biological mechanisms does not eliminate the importance of lifestyle habits, but it shifts the discussion from blame to care. And that brings us to the potentially most revolutionary aspect of this new era: showing that treating obesity does not simply mean getting someone to eat less, but rather understanding, in much greater depth, why eating can be such a different experience from one person to the next.
“GLP-1–based medications (or dual GIP/GLP-1 agonism) do not close the discussion on obesity. They usher in a more scientific, less moralistic and potentially more humane kind of medicine for caring for people living with this disease,” the endocrinologist concludes.
Scientific studies cited or used for supplementary information:
- “Food noise: definition, measurement, and future research directions.” Available at https://pmc.ncbi.nlm.nih.gov/articles/PMC12238327/
- “What Is Food Noise? A Conceptual Model of Food Cue Reactivity.” Available at https://pmc.ncbi.nlm.nih.gov/articles/PMC10674813/
- “Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey.” Available at https://pubmed.ncbi.nlm.nih.gov/42217114/
